Compare · ACXP vs AZN
ACXP vs AZN
Side-by-side comparison of Acurx Pharmaceuticals Inc. (ACXP) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACXP and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $282.65B, about 47379.7x ACXP ($6.0M).
- AZN has been more active in the news (22 items in the past 4 weeks vs 6 for ACXP).
- AZN has more recent analyst coverage (25 ratings vs 1 for ACXP).
- Company
- Acurx Pharmaceuticals Inc.
- AstraZeneca PLC
- Price
- -
- -
- Market cap
- $6.0M
- $282.65B
- 1M return
- -
- +11.17%
- 1Y return
- -
- +104.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2026
- News (4w)
- 6
- 22
- Recent ratings
- 1
- 25
Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest ACXP
- New to The Street Show #780 Premieres Tonight on Bloomberg Television with Robo.ai, American Fusion, Stewards Investment Capital and FreeCast
- Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
- SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.
- SEC Form 8-K filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
- Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
- SEC Form 8-K filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
- SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC